Cardiovascular effects of thiazolidinediones

Pitiporn Suwattee, Cyrus DeSouza, Sunil Asnani, Lucia Gilling, Vivian A. Fonseca

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

The thiazolidinediones are a new class of compounds approved for the treatment of type 2 diabetes. Because these drugs directly improve insulin resistance and decrease plasma insulin concentration, they have the potential to decrease the risk for cardiovascular disease in diabetic patients. A number of studies have demonstrated changes in several cardiovascular risk factors associated with the insulin resistance syndrome. These effects include decreasing of blood pressure, correcting diabetic dyslipidemia, improving fibrinolysis, and decreasing carotid artery intima-medial thickness. Other in vitro effects related to their ability to bind a newly described class of receptors (peroxisome proliferator-activated receptors) may also have implications for atherosclerosis. Although these drugs increase low-density lipoprotein (LDL) cholesterol, they induce a favorable change in the LDL particle size and susceptibility to oxidation. The implications of these changes are not clear. Because of their mechanism of action, clinical trials have been designed to determine whether these drugs (or similar "insulin sensitizers") will decrease cardiovascular events in people with type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)126-134
Number of pages9
JournalEndocrinologist
Volume12
Issue number2
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Thiazolidinediones
Type 2 Diabetes Mellitus
Insulin Resistance
Pharmaceutical Preparations
Insulin
Peroxisome Proliferator-Activated Receptors
Fibrinolysis
Dyslipidemias
LDL Lipoproteins
Carotid Arteries
Particle Size
LDL Cholesterol
Atherosclerosis
Cardiovascular Diseases
Clinical Trials
Blood Pressure
Therapeutics

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Suwattee, P., DeSouza, C., Asnani, S., Gilling, L., & Fonseca, V. A. (2002). Cardiovascular effects of thiazolidinediones. Endocrinologist, 12(2), 126-134. https://doi.org/10.1097/00019616-200203000-00011

Cardiovascular effects of thiazolidinediones. / Suwattee, Pitiporn; DeSouza, Cyrus; Asnani, Sunil; Gilling, Lucia; Fonseca, Vivian A.

In: Endocrinologist, Vol. 12, No. 2, 01.01.2002, p. 126-134.

Research output: Contribution to journalReview article

Suwattee, P, DeSouza, C, Asnani, S, Gilling, L & Fonseca, VA 2002, 'Cardiovascular effects of thiazolidinediones', Endocrinologist, vol. 12, no. 2, pp. 126-134. https://doi.org/10.1097/00019616-200203000-00011
Suwattee, Pitiporn ; DeSouza, Cyrus ; Asnani, Sunil ; Gilling, Lucia ; Fonseca, Vivian A. / Cardiovascular effects of thiazolidinediones. In: Endocrinologist. 2002 ; Vol. 12, No. 2. pp. 126-134.
@article{0a947502e0ed42f89506b00c8605137f,
title = "Cardiovascular effects of thiazolidinediones",
abstract = "The thiazolidinediones are a new class of compounds approved for the treatment of type 2 diabetes. Because these drugs directly improve insulin resistance and decrease plasma insulin concentration, they have the potential to decrease the risk for cardiovascular disease in diabetic patients. A number of studies have demonstrated changes in several cardiovascular risk factors associated with the insulin resistance syndrome. These effects include decreasing of blood pressure, correcting diabetic dyslipidemia, improving fibrinolysis, and decreasing carotid artery intima-medial thickness. Other in vitro effects related to their ability to bind a newly described class of receptors (peroxisome proliferator-activated receptors) may also have implications for atherosclerosis. Although these drugs increase low-density lipoprotein (LDL) cholesterol, they induce a favorable change in the LDL particle size and susceptibility to oxidation. The implications of these changes are not clear. Because of their mechanism of action, clinical trials have been designed to determine whether these drugs (or similar {"}insulin sensitizers{"}) will decrease cardiovascular events in people with type 2 diabetes.",
author = "Pitiporn Suwattee and Cyrus DeSouza and Sunil Asnani and Lucia Gilling and Fonseca, {Vivian A.}",
year = "2002",
month = "1",
day = "1",
doi = "10.1097/00019616-200203000-00011",
language = "English (US)",
volume = "12",
pages = "126--134",
journal = "Endocrinologist",
issn = "1051-2144",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Cardiovascular effects of thiazolidinediones

AU - Suwattee, Pitiporn

AU - DeSouza, Cyrus

AU - Asnani, Sunil

AU - Gilling, Lucia

AU - Fonseca, Vivian A.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - The thiazolidinediones are a new class of compounds approved for the treatment of type 2 diabetes. Because these drugs directly improve insulin resistance and decrease plasma insulin concentration, they have the potential to decrease the risk for cardiovascular disease in diabetic patients. A number of studies have demonstrated changes in several cardiovascular risk factors associated with the insulin resistance syndrome. These effects include decreasing of blood pressure, correcting diabetic dyslipidemia, improving fibrinolysis, and decreasing carotid artery intima-medial thickness. Other in vitro effects related to their ability to bind a newly described class of receptors (peroxisome proliferator-activated receptors) may also have implications for atherosclerosis. Although these drugs increase low-density lipoprotein (LDL) cholesterol, they induce a favorable change in the LDL particle size and susceptibility to oxidation. The implications of these changes are not clear. Because of their mechanism of action, clinical trials have been designed to determine whether these drugs (or similar "insulin sensitizers") will decrease cardiovascular events in people with type 2 diabetes.

AB - The thiazolidinediones are a new class of compounds approved for the treatment of type 2 diabetes. Because these drugs directly improve insulin resistance and decrease plasma insulin concentration, they have the potential to decrease the risk for cardiovascular disease in diabetic patients. A number of studies have demonstrated changes in several cardiovascular risk factors associated with the insulin resistance syndrome. These effects include decreasing of blood pressure, correcting diabetic dyslipidemia, improving fibrinolysis, and decreasing carotid artery intima-medial thickness. Other in vitro effects related to their ability to bind a newly described class of receptors (peroxisome proliferator-activated receptors) may also have implications for atherosclerosis. Although these drugs increase low-density lipoprotein (LDL) cholesterol, they induce a favorable change in the LDL particle size and susceptibility to oxidation. The implications of these changes are not clear. Because of their mechanism of action, clinical trials have been designed to determine whether these drugs (or similar "insulin sensitizers") will decrease cardiovascular events in people with type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=0036200177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036200177&partnerID=8YFLogxK

U2 - 10.1097/00019616-200203000-00011

DO - 10.1097/00019616-200203000-00011

M3 - Review article

AN - SCOPUS:0036200177

VL - 12

SP - 126

EP - 134

JO - Endocrinologist

JF - Endocrinologist

SN - 1051-2144

IS - 2

ER -